10049-61-3

Upstream product

• 76947-33-6 [(R)-2-Methyl-cyclohex-(Z)-ylidene]-(1-phenyl-ethyl)-amine 
• 79265-63-7 ((1S,2R)-2-Methyl-cyclohexyl)-((S)-1-phenyl-ethyl)-amine; hydrochloride 
• 79265-63-7 ((1S,2R)-2-Methyl-cyclohexyl)-((S)-1-phenyl-ethyl)-amine; hydrochloride 
• 195251-76-4 E/Z-<2(RS)>-2-Methyl-N-(S-α-methylbenzyl)-cyclohexaneimine 
• 828291-16-3 E/Z-<2(RS)>-2-Methyl-N-(R-α-methylbenzyl)-cyclohexaneimine 
• 583-60-8 2-Methylcyclohexanone 

Downstream Products

• 1263419-74-4 4-(2-methylcyclohexylamino)-6-nitropyrrolo[1,2-b]pyridazine-3-carbonitrile 
• 1263420-04-7 ethyl 3-cyano-4-(2-methylcyclohexylamino)pyrrolo[1,2-b]pyridazine-7-carboxylate 
• 1263420-01-4 4-(2-methylcyclohexaneamino)pyrrolo[1,2-b]pyridazine-3-carbonitrile 

Relevant academic research and scientific papers

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Asymmetric Reductive Amination of Cycloalkanones, III: Influence of Catalyst and Reducing Agent on the Diastereo- and Enatioselectivity

The dependence of diastereo- and enantioselectivity in the asymmetric reductive amination of racemic 2-methylcyclohexanone (1) on the type of catalyst and reducing agent has been investigated.Diastereo- and enatioselectivity were determined by (13)C-NMR s

ASYMMETRIC SYNTHESIS OF CIS-2-SUBSTITUTED CYCLOHEXANAMINES WITH HIGHT OPTICAL PURITY

Asymmetric reductive amination of racemic 2-substituted cyclohexanones (R= methyl, ethyl, phenyl, benzyl) using optically active 1-phenyl-ethylamines yields optically active cis-cyclohexanamines.